Browse by Series:

FDA Approval of Frontline Osimertinib in Frontline EGFR-Mutant NSCLC

Gina Columbus
Published: Thursday, Apr 19, 2018



Hello and welcome to OncLive News Network, Breaking News. I'm Gina Columbus.

The FDA has granted an approval to osimertinib as a first-line treatment for patients with non-small cell lung cancer whose tumors harbor EGFR mutations with exon 19 deletions or exon 21 L858R substitution mutations.

The decision is based on findings of the phase III FLAURA study, in which frontline osimertinib reduced the risk of progression or death by 54% versus standard tyrosine kinase inhibitor erlotinib or gefitinib.

In the double-blind study, the median progression-free survival was 10.2 months for standard therapy and 18.9 months with osimertinib.

The PFS benefit with osimertinib extended across all prespecified subgroups. In patients with CNS metastases, the median PFS with osimertinib was 15.2 months versus 9.6 months with standard therapy.

The objective response rate with osimertinib was 80% versus 76% for erlotinib and gefitinib. The median duration of response with osimertinib was 17.2 months versus 8.5 months in the comparator arm.

For more breaking news, subscribe to email alerts from OncLive.com. Thank you for watching! I'm Gina Columbus.
SELECTED
LANGUAGE
Slider Left
Slider Right


Hello and welcome to OncLive News Network, Breaking News. I'm Gina Columbus.

The FDA has granted an approval to osimertinib as a first-line treatment for patients with non-small cell lung cancer whose tumors harbor EGFR mutations with exon 19 deletions or exon 21 L858R substitution mutations.

The decision is based on findings of the phase III FLAURA study, in which frontline osimertinib reduced the risk of progression or death by 54% versus standard tyrosine kinase inhibitor erlotinib or gefitinib.

In the double-blind study, the median progression-free survival was 10.2 months for standard therapy and 18.9 months with osimertinib.

The PFS benefit with osimertinib extended across all prespecified subgroups. In patients with CNS metastases, the median PFS with osimertinib was 15.2 months versus 9.6 months with standard therapy.

The objective response rate with osimertinib was 80% versus 76% for erlotinib and gefitinib. The median duration of response with osimertinib was 17.2 months versus 8.5 months in the comparator arm.

For more breaking news, subscribe to email alerts from OncLive.com. Thank you for watching! I'm Gina Columbus.
View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Rapid Reviews in Oncology®: Practice-Changing Data in Acute Myeloid Leukemia: A Rapid Update From Atlanta OnlineDec 21, 20182.0
Community Practice Connections™: 2nd Annual European Congress on Hematology™: Focus on Lymphoid MalignanciesDec 30, 20182.0
Publication Bottom Border
Border Publication
x